This technology is a method to generate squamous epithelial 3D organoids that can mimic the natural physiology of tissues and be used as a personalized pathology model.
This technology is an in vitro platform for studying pancreatic cancer in a patient-specific manner for personalized medicine approaches.
This technology is a nucleic acid-based polymer system that can be engineered to target the expression of specific cancer-associated genes for therapeutic benefit.
This technology combines anti-androgen therapy with epigenetic modification for the treatment or prevention of neuroendocrine prostate cancer.
This technology is a cancer immunotherapy platform that activates CD28-CD8+ T-cells via the CD58:CD2 axis.
This technology is a CRISPR gene editing approach to enhance regulatory T-cell (Treg) and CAR Treg stability to create safer and more effective immunosuppressive therapies for transplantation and autoimmunity.
This technology is an ex vivo platform for selection and amplification of tumor-infiltrating lymphocytes with tumor-killing ability that can be used to optimize immunotherapy before administration to the patient.
This technology is a small molecule that selectively targets the mitogen-activated protein kinase (MAPK) core pathways, regulated by Germinal Center Kinase (GCK), and inhibits cell growth for treatment of cancers, notably multiple myeloma.
This technology is a therapeutic platform that enables the selective removal of diseased or cancerous cells with few side effects.
This technology is a set of master regulators of tumor regulatory T cell infiltration that can be targeted for cancer treatment.
This technology is a strategy for selective T cell repopulation that enhances immunotherapy by quantifying and expanding progenitor T cells within tumors and peripheral blood in conjunction with immunotherapy.
This technology describes a method to generate patient-derived oral cancer organoids, facilitating disease modeling and drug screening via a personalized medicine approach.
This technology decreases the infiltration of suppressive immune cells at the tumor site by blocking IL-8 and/or its receptors, potentially improving treatment outcomes for prostate cancer.
This technology is an immunotherapy strategy to stop bone loss by selective osteoclast inhibition.
This technology is collection of small molecule PI 3-kinase (PI3K) inhibitors for treating T-cell acute lymphoblastic leukemia (T-ALL).